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Background: Genome-wide association studies have identified that genetic variants in 8q24 confer susceptibility to
colorectal cancer (CRC). Recently, a novel lncRNA (PRNCR1) that located in the 8q24 was discovered. Single
nucleotide polymorphisms (SNPs) in the lncRNAs may influence the process of splicing and stability of mRNA
conformation, resulting in the modification of its interacting partners. We hypothesized that SNPs in the lncRNA
PRNCR1 may be related to the risk of CRC.
Methods: We conducted a case–control study and genotyped five tag SNPs in the lncRNA PRNCR1 in 908 subjects
including 313 cases with CRC and 595 control subjects using polymerase chain reaction–restriction fragment length
polymorphism (PCR-RFLP) assay.
Results: In overall analyses, we found that the rs13252298 and rs1456315 were associated with significantly
decreased risks of CRC. In stratification analyses, we found that CRC patients carrying the rs1456315G were likely to
have a tumor size of greater than 5 cm (G vs. A: adjusted OR = 1.56, 95% CI: 1.10-2.23). Additionally, patients with
the rs7007694C and rs16901946G had decreased risks to develop poorly differentiated CRC, whereas patients with
the rs1456315G had an increased risk to develop poorly differentiated CRC.
Conclusion: These findings suggest that SNPs in the lncRNA PRNCR1 may contribute to susceptibility to CRC.
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Cancer including colorectal cancer (CRC) is a disease ac-
cumulated with multistep genetic and epigenetic level
changes and with a complex etiology [1]. Genome-wide
association scans and subsequent observational replica-
tion studies have identified that genetic variants located
at the chromosomal region 8q24 confer susceptibility
to CRC [2-17]. However, the region was called “gene-
desert” area because it does not harbor any candidate* Correspondence: zhanglin@scu.edu.cn; cdchglb@gmail.com
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stated.gene except for the putative gene POU5F1P1 whose func-
tion is unknown [18], causing the function of the varia-
tions in the susceptibility loci is not well established.
Recently, a ~13 kb long non-coding RNAs (lncRNA)
was discovered that was transcribed from the “gene-
desert” region of chromosome 8q24 (128.14-128.28 Mb)
[19]. The lncRNA, termed prostate cancer non-coding
RNA 1 (PRNCR1), was reported to be involved in the car-
cinogenesis of prostate cancer [19]. Therefore, further
characterization of lncRNA related single nucleotide poly-
morphisms (SNPs) may open a new avenue for functional
analysis of cancer susceptibility loci identified by genome-
wide association study, especially when it was located in
introns or “gene-desert” region.
LncRNAs are RNA polymerase II-transcribed, polya-
denylated, and frequently alternatively spliced RNAs
[20,21] with the features of cell-type specific expressionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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linkage to various diseases [25], and evolutionary selec-
tion of the lncRNA sequence [26,27]. LncRNAs can be
intergenic, intronic, antisense or overlapping with protein-
coding genes or other ncRNAs [26,28-30]. Recent studies
have revealed the contribution of ncRNAs as proto-
oncogene [31], tumor suppressor gene [32], drivers of
metastasis transformation in cancer development [33].
The expression of lncRNAs is deregulated in different
cancers, including colon cancer [34]. Several lines of
evidence have shown that SNPs in lncRNAs may influ-
ence the process of splicing and stability of mRNA con-
formation, resulting in the modification of its interacting
partners [19,35].
In this study, we hypothesized that SNPs in lncRNAs
may be involved in the risk of CRC. To test this hypoth-
esis, we selected five tag SNPs in the lncRNA PRNCR1
in the “gene-desert” region of 8q24 (i.e., rs1016343,
rs13252298, rs7007694, rs16901946, and rs1456315),
and genotyped the SNPs in a case–control study of 313




Totally, 908 subjects attended our case–control study
comprising 313 cases (313 patients with CRC including
199 males and 114 females) and 595 control subjects
(289 males and 306 females). Diagnosis of CRC was con-
firmed by histopathological examination and those who
had inflammatory bowel disease were excluded. Patients
were recruited from the Luoyang Central Hospital and
the West China Hospital, Sichuan University between
January 2010 and February 2012. Control subjects in-
cluding 595 healthy volunteers who came to the West
China Hospital just for routine check-up during the
same time as the patients. Individuals were excluded if
there was any evidence of personal or family history of
cancer or inflammatory diseases in the intestine, such as
ulcerative colitis or Crohn’s colitis. There was no signifi-
cant difference between patients and control subjects in
terms of ethnicity distribution. Written informed con-
sent was obtained from all subjects attending this study,
and the study was performed with the approval of the
ethics committee of the hospital.
Selection of SNPs
We searched tag SNPs in the lncRNAs PRNCR1 in the
chromosomal region 8q24 using UCSC (http://genome.
ucsc.edu/) with the selection criteria of the minor allele
frequency more than 0.10 in Asians. Finally, five tag SNPs
were identified: rs1016343 (Chr8-128162479), rs13252298
(Chr8-128164338), rs7007694 (Chr8-128168348), rs16901946
(Chr8- 128170107), and rs1456315 (Chr8-128173119).Genotyping
2 mL peripheral blood used for genotyping assay was
obtained from each subject after their admission to the
hospital, and each subject was interviewed to obtain
demographic and clinical information. Genomic DNA
was extracted from the blood of the subjects using a
commercial extraction kit (Bioteke Corporation, Beijing,
China) according to the manufacturer’s directions. We
used a polymerase chain reaction–restriction fragment
length polymorphism (PCR-RFLP) assay to acquire all the
genotypes of the five SNPs (i.e., rs1016343, rs13252298,
rs7007694, rs16901946, and rs1456315). Primer sequences,
reaction conditions, restriction enzymes (New England
BioLabs Inc; Beverly, MA, USA.) and length of polymerase
chain reaction products are summarized in Additional
file 1: Table S1. Restriction fragments were distinguished
on 6% polyacrylamide gels and visualized by silver staining
to identify the genotypes. For quality control, the PCR
products of the five SNPs with different genotypes were
confirmed by DNA sequencing, and the results were 100%
concordant. Additionally, 10% of the whole samples were
repeated, and positive and negative controls were used in
each 96-well PCR plate.
Statistical analysis
Allele and genotype frequencies of the five SNPs were
obtained using Modified-Powerstates standard edition
software. Hardy-Weinberg equilibrium was tested with
a goodness of fit chi-square test (with one degree of
freedom) to compare the observed genotype frequen-
cies among the subjects with the expected genotype
frequencies. The demographic and clinical data of the
two groups were compared using the chi-square test.
Bivariate logistic regression was used to calculate the
odds ratios (ORs), 95% confidence intervals (CIs), and
corresponding p values after adjustment for age and gen-
der. P < 0.05 is considered statistically significant. All
data were analyzed using the SPSS for Windows soft-
ware package version 13.0 (SPSS Inc., Chicago. IL).
Results
The five SNPs of rs1016343, rs13252298, rs7007694,
rs16901946, and rs1456315 in 8q24 were successfully ge-
notyped for 908 subjects. The clinical features of sub-
jects enrolled in our study are shown in Table 1. The
genotype frequencies of the five polymorphisms in the
control group met the requirements of the Hardy-
Weinberg equilibrium (P >0.05). The genotype and allele
frequencies of the five SNPs are summarized in Table 2.
The AG genotype and G allele of rs13252298 were asso-
ciated with a significantly decreased risk of CRC, com-
pared with the AA genotype and A allele (AG vs. AA,
adjusted OR = 0.67, 95% CI: 0.49-0.91, p = 0.01; G vs. A, ad-
justed OR = 0.75, 95% CI: 0.60-0.94, p = 0.01, respectively).
Table 1 Demographics of patients with CRC and controls
Variables Controls n = 595 (%) CRC n = 313 (%)
















Table 2 Genotype and allele frequencies of the five SNPs
between cases and controls
Polymorphisms Controls
(n = 595) (%)






CC 227(38.1) 117(37.4) 1.0(ref)
CT 276(46.4) 156(49.8) 1.33(0.82-2.14) 0.25
TT 92(15.5) 40(12.8) 1.13(0.83-1.55) 0.44
C 730(61.3) 390(62.3) 1.0(ref)
T 460(38.7) 236(37.7) 1.14(0. 92–1.41) 0.24
rs13252298
AA 264(44.4) 166(53.0) 1.0(ref)
AG 270(45.4) 121(38.7) 0.67(0.49-0.91) 0.01
GG 61(10.2) 26(8.3) 0.64(0.38-1.09) 0.10
A 798(67.1) 453(72.4) 1.0(ref)
G 392(32.9) 173(27.6) 0.75(0.60-0.94) 0.01
rs7007694
TT 362(60.8) 184(58.8) 1.0(ref)
CT 208(35.0) 107(34.2) 1.04(0.76-1.42) 0.80
CC 25(4.2) 22(7.0) 1.60(0.85-3.03) 0.15
T 932(78.3) 475(75.9) 1.0(ref)
C 258(21.7) 151(24.1) 1.15(0.90-1.46) 0.27
rs16901946
AA 338(56.8) 175(55.9) 1.0(ref)
AG 232(39.0) 117(37.4) 0.96(0.71-1.31) 0.80
AG/GG 257(43.2) 138(44.1) 1.03(0.77-1.38) 0.85
A 908(76.3) 467(74.6) 1.0(ref)
G 282(23.7) 159(25.4) 1.10(0.86-1.39) 0.45
rs1456315
AA 294(49.4) 167(53.4) 1.0(ref)
AG 262(44.0) 119(38.0) 0.66(0.48-0.90) 0.01
GG 39(6.6) 27(8.6) 1.09(0.62-1.91) 0.78
A 850(71.4) 453(72.4) 1.0(ref)
G 340(28.6) 173(27.6) 0.86(0.70-1.08) 0.18
OR: odds ratio; CI: confidence interval; Ref: reference.
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ated with a significantly decreased risk of CRC, compared
with the AA genotype (AG vs. AA, adjusted OR = 0.66,
95% CI: 0.48-0.90, p = 0.01). However, no significant asso-
ciation was observed between the other SNPs and risk of
CRC. Besides, we examined the linkage disequilibrium
(LD) plot,and the 5 SNPs was not in LD (data not shown).
When patients were divided according to tumor size,
differentiated status, clinical stage, and metastasis status,
we found that CRC patients carrying the rs1456315G
allele were likely to have a tumor size of greater than
5 cm (G vs. A: adjusted OR = 1.56, 95% CI: 1.10-2.23).
Additionally, patients with the rs7007694C allele and
rs16901946G allele had a decreased risk to develop
poorly differentiated CRC (rs7007694 C vs. T: adjusted
OR = 0.46, 95% CI: 0.28-0.77; rs16901946 G vs. A: ad-
justed OR = 0.59, 95% CI: 0.37-0.94, respectively). Inter-
estingly, patients with the rs1456315G allele had an
increased risk to develop poorly differentiated CRC
(adjusted OR = 1.54, 95% CI: 1.03-2.31) (Table 3).
Discussion
In the present study, for the first time, we provided evi-
dence that SNPs (i.e., rs13252298, rs7007694, rs16901946,
and rs1456315) in the lncRNA PRNCR1 at the “gene-
desert” region in 8q24 might be associated with CRC sus-
ceptibility. We identified the rs13252298 and rs1456315
were associated with significantly decreased risks of CRC.
In stratification analyses, we found that the rs1456315
was related to the tumor size of CRC. Moreover, pa-
tients with the rs7007694C allele and rs16901946G allele
had decreased risks to develop poorly differentiated CRC,whereas patients with the rs1456315G allele had an in-
creased risk to develop poorly differentiated CRC. These
findings indicate that the polymorphisms in the lncRNA
PRNCR1 may be related to the development of CRC, of-
fering a novel and potential strategy for functional analysis
of susceptibility loci to human diseases.
It has been shown that lncRNAs have developmen-
tal and tissue specific expression patterns, with an ab-
errant regulation in various diseases, including cancer
[24,36-44]. LncRNAs have been reported to be involved
in cancer development in three different ways: Firstly,
some lncRNAs take part in the process as oncogene or
oncogene regulator, for example, MALAT1 gene in non-
Table 3 Stratified analyses of lncRNA PRNCR1 polymorphisms with clinical features in patients with CRC
(minor allele vs. major allele)
Polymorphisms Adjusted OR for age and gender (95% CI)/p
Tumor size (≥5 cm) Differentiated status (poorly) Clinical stage (III-IV) Metastasis (yes)
rs1016343C/T 0.82(0.59-1.13)/0.22 1.05(0.72-1.55)/0.79 1.07(0.77-1.49)/0.70 1.27(0.91-1.78)/0.16
rs13252298A/G 1.07(0.75-1.52)/0.72 1.21(0.80-1.82)/0.37 0.85(0.59-1.21)/0.36 0.76(0.53-1.10)/0.15
rs7007694T/C 0.74(0.51-1.08)/0.11 0.46(0.28-0.77)/0.003 1.04(0.71-1.51)/0.85 1.11(0.76-1.62)/0.59
rs16901946A/G 0.84(0.59-1.22)/0.36 0.59(0.37-0.94)/0.03 1.09(0.76-1.58)/0.64 1.26(0.87-1.83)/0.22
rs1456315A/G 1.56(1.10-2.23)/0.01 1.54(1.03-2.31)/0.04 1.16(0.81-1.66)/0.43 1.06(0.73-1.52)/0.77
CRC: colorectal cancer; OR: odds ratio; CI: confidence interval.
The smaller size, well differentiated status, clinical stage I-II, and the ones without metastasis were made as references, respectively.
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The expression of MALAT1 was up-regulated in many
kinds of human cancers such as breast cancer, prostate
cancer, colon cancer, liver cancer, and uterus cancer
[44,47-49]. Mice lacking H19 presented an increased polyp
count which is related to CRC [50]. Secondly, lncRNA
may be related to cancer metastasis or prognosis. Gupta
et al. reported a lncRNA HOTAIR which was associated
with cancer metastasis and poor survival [33]. Thirdly,
lncRNAs appear as tumor suppressor gene: MEG3 is the
first lncRNA proposed to function as a tumor suppressor
and also a top level regulatory RNA because of its ability
stimulating both p53-dependent and p53-independent
pathways [32,51]. Recurring chromosomal aberrations can
influence the expression of many lncRNAs, such as dis-
rupted in schizophrenia 1 and 2 (DISC1 and DISC2),
which were involved in the development of various dis-
eases [52,53]. For instance, a large number of SNPs in the
DISC1 genomic sequence have been reported to be associ-
ated with schizophrenia spectrum disorder [54,55].
Emerging evidence has demonstrated that SNPs lo-
cated in non-coding regions may be used as susceptibil-
ity factors to several diseases. Scott et al. reported that
SNPs adjacent to the lncRNA ANRIL were associated
with increased risks of type 2 diabetes [56]. The view-
point was also confirmed by a separate study, which
reported that distinct SNPs in the lncRNA ANRIL
locus were associated with susceptibility to coronary artery
disease and atherosclerosis [57]. Further characterization
of the identified polymorphisms showed that SNPs can
disrupt ANRIL splicing, leading to a circular transcript that
is resistant to RNase digestion [35]. The circularized tran-
scripts have effect on ANRIL normal function and influ-
ence INK4/ARF expression. Other evidence is from the
recent study of leukemia and CRC which identified both
germline and somatic mutations in lncRNA genes [58].
Recently, a novel lncRNA, named PRNCR1, has been
discovered and was reported to be up-regulated in pros-
tate cancer [19]. SNPs in the lncRNA PRNCR1 gene might
influence the predicted secondary structure of PRNCR1
mRNA, alter the stability of the lncRNA PRNCR1 orthe mRNA conformation, and result in the modifica-
tion of its interacting partners [19]. Since the lncRNA
PRNCR1 located in 8q24 which was a susceptibility
locus to CRC [2-17,59], we hypothesized that SNPs in this
region may have roles in the development of CRC. Our
findings confirmed our hypothesis. We found that tag
SNPs in the lncRNA PRNCR1 may be a protective factor
against CRC, suggesting that SNPs in lncRNA may be
involved in the tumorigenesis of CRC. Although Chung
and colleague’s report suggested that the lncRNA PRNCR1
was associated with prostate carcinogenesis and may
play a role through the regulation of androgen recep-
tor (AR) transactivation activity [19], no report inves-
tigated the relationship between the region 2 of 8q24
and CRC risk. Moreover, there were reports suggested
that AR also participated in the pathologic process of
CRC through TGFβ pathway [60,61]. In this study, we
found that the rs1456315 was also associated with clinical
features of CRC, which was consistent with the report by
Chung et al. [19].
Although we detected the association between SNPs
in lncRNA and CRC, there were limitations needed to
be mentioned in our study. One is that the follow-up
information is blank, which limited our further ana-
lysis on the association between SNPs in lncRNA and
CRC prognosis. Another is that the study subjects are
all ethnic Han Chinese, and the sample size is moder-
ate. Further large-scale studies in different popula-
tions, therefore, still need to be done.
Conclusion
In conclusion, we found that the variant genotypes of
rs13252298 and rs1456315 may contribute to a decreased
risk of CRC. Moreover, the rs7007694, rs16901946, and
rs1456315 polymorphisms were associated with the tumor
size and differentiated status of patients. Association stud-
ies with diverse populations and further functional ana-
lysis of the variants are needed to verify our findings.
Once our understanding of lncRNAs language is clear, we
will be able to classify diseases based on the identified mu-
tations and their effect on lncRNA function.
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